Therefore, blood-based biomarker tools can meet the scalability requirements for broad population-based screening and offer the opportunity to measure a wide range of potential pathophysiological biomarkers involved in multifactorial AD molecular mechanisms beyond conventional Aβ and tau pathologies. This evidence concerns the gene MAPT and Alzheimer disease.